Pfizer Still Looking To Buy A Tax Advantage – And Before Congress Flips
This article was originally published in Scrip
Pfizer Inc. CEO Ian Read said the company is evaluating tax inversion M&A opportunities but noted the big pharma would need to complete such a deal by the end of 2016, after which a new Congress would be in place – presenting further regulatory risks.
You may also be interested in...
Investors are closely following a Phase III study testing Wainua in ATTR cardiomyopathy, which could read out early in 2025.
It’s early days in the launch of Zurzuvae for postpartum depression, but Sage highlighted encouraging prescription trends during the company’s fourth quarter sales and earnings call.
The company is looking to spend some of the cash it earned on the sale of Telavant on new assets that will join the late-stage pipeline.